- Home
- CHMI vs IMUX Comparison
CHMI vs IMUX Comparison
Compare CHMI & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHMI
- IMUX
- Stock Information
- Founded
- CHMI 2012
- IMUX 2016
- Country
- CHMI United States
- IMUX United States
- Employees
- CHMI N/A
- IMUX N/A
- Industry
- CHMI Real Estate Investment Trusts
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- CHMI Real Estate
- IMUX Health Care
- Exchange
- CHMI Nasdaq
- IMUX Nasdaq
- Market Cap
- CHMI 92.0M
- IMUX 102.2M
- IPO Year
- CHMI 2013
- IMUX N/A
- Fundamental
- Price
- CHMI $3.30
- IMUX $1.09
- Analyst Decision
- CHMI Buy
- IMUX Strong Buy
- Analyst Count
- CHMI 3
- IMUX 7
- Target Price
- CHMI $5.00
- IMUX $12.67
- AVG Volume (30 Days)
- CHMI 344.9K
- IMUX 555.7K
- Earning Date
- CHMI 03-06-2025
- IMUX 05-07-2025
- Dividend Yield
- CHMI 18.21%
- IMUX N/A
- EPS Growth
- CHMI N/A
- IMUX N/A
- EPS
- CHMI 0.07
- IMUX N/A
- Revenue
- CHMI $46,993,000.00
- IMUX N/A
- Revenue This Year
- CHMI $14.91
- IMUX N/A
- Revenue Next Year
- CHMI N/A
- IMUX N/A
- P/E Ratio
- CHMI $48.24
- IMUX N/A
- Revenue Growth
- CHMI N/A
- IMUX N/A
- 52 Week Low
- CHMI $2.50
- IMUX $0.92
- 52 Week High
- CHMI $3.99
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- CHMI 36.67
- IMUX 46.81
- Support Level
- CHMI $3.54
- IMUX $1.18
- Resistance Level
- CHMI $3.67
- IMUX $1.28
- Average True Range (ATR)
- CHMI 0.10
- IMUX 0.07
- MACD
- CHMI -0.03
- IMUX -0.00
- Stochastic Oscillator
- CHMI 10.59
- IMUX 6.00
About CHMI Cherry Hill Mortgage Investment Corporation
Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.